A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the first-ever U.S. law ...

Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

The stock's fall snapped a five-day winning streak.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Given this outlook, focusing on high-yield dividend stocks and cautious valuation is essential for long-term investment ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

If a company shows a lot of potential, investors are often willing to pay a premium and take on some risk in exchange for ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $117.96 which represents a slight increase of $2.10 or 1.81% from the prior close of $115.86. The stock opened at $115.8 and touched a ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...